Over the past decade, Poland has become a key location for clinical trials and pharmaceutical manufacturing within global development and supply chains. As a result, Polish clinical sites and pharmaceutical companies are increasingly subject to inspections conducted by international regulatory authorities, most notably the U.S. Food and Drug Administration (FDA) and European regulatory agencies operating within the EU framework. Although these inspections take place on Polish soil, their operational language is almost invariably English.
You are browsing archives for